P7N4-Pen

P7N4-Pen is a synthetic peptide derived from a functional motif of Signaling Lymphocytic Activation Molecule Family 1 (SLAMF1) with a single amino acid substitution (Y4N) and linked to the cell-penetrating peptide Penetratin (Pen) for intracellular delivery. Developed by the Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital, P7N4-Pen is being investigated as a novel therapeutic candidate for the treatment of multiple myeloma (MM). Mechanistically, P7N4-Pen directly binds to and targets the oncogenic transcription factor Interferon Regulatory Factor 4 (IRF4) for degradation. This direct interaction disrupts key pro-survival pathways in MM cells, leading to the downregulation of downstream oncogenes such as MYC and β-catenin, and the inhibition of Akt and ERK1/2 phosphorylation, ultimately inducing both extrinsic and intrinsic apoptosis. In preclinical studies, P7N4-Pen has demonstrated potent anti-cancer activity against various human myeloma cell lines, including those resistant to proteasome inhibitors, and primary CD138+ patient-derived tumor cells, while sparing healthy peripheral blood mononuclear cells. It also exhibits synergistic effects when combined with chemotherapeutic agents like melphalan or proteasome inhibitors like bortezomib.

Other names

P7N4 peptideP-7N4 peptideP 7N4 peptideSLAMF1-derived peptide P7N4SLAMF-1-derived peptide P7N4SLAMF 1-derived peptide P7N4SLAMF1-derived peptide P7N4-PenSLAMF-1-derived peptide P7N4-PenSLAMF 1-derived peptide P7N4-Pen